Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Applied Dna Scns (APDN)

Applied Dna Scns (APDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,261
  • Shares Outstanding, K 52,294
  • Annual Sales, $ 13,370 K
  • Annual Income, $ -9,950 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.46
  • Price/Sales 2.85
  • Price/Cash Flow N/A
  • Price/Book 0.65
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.84
  • Most Recent Earnings $-0.32 on 12/17/24
  • Next Earnings Date 02/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 174.67%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -1.80
  • Growth Rate Est. (year over year) +82.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1204 +47.09%
on 12/13/24
0.2500 -29.16%
on 12/18/24
+0.0121 (+7.33%)
since 11/20/24
3-Month
0.1204 +47.09%
on 12/13/24
1.2500 -85.83%
on 09/23/24
-1.0679 (-85.78%)
since 09/20/24
52-Week
0.1204 +47.09%
on 12/13/24
14.4000 -98.77%
on 02/23/24
-12.0189 (-98.55%)
since 12/20/23

Most Recent Stories

More News
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNAâ„¢ as a Rapid and Effective Means of Producing CAR-T cell Therapies -

APDN : 0.1771 (-5.29%)
Applied DNA Sciences: Fiscal Q4 Earnings Snapshot

Applied DNA Sciences: Fiscal Q4 Earnings Snapshot

APDN : 0.1771 (-5.29%)
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -

APDN : 0.1771 (-5.29%)
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced...

APDN : 0.1771 (-5.29%)
Applied DNA Sciences: Fiscal Q3 Earnings Snapshot

Applied DNA Sciences: Fiscal Q3 Earnings Snapshot

APDN : 0.1771 (-5.29%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1771 (-5.29%)
MRVI : 5.37 (-1.10%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1771 (-5.29%)
MRVI : 5.37 (-1.10%)
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML

STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT)...

APDN : 0.1771 (-5.29%)
Applied DNA Sciences: Fiscal Q2 Earnings Snapshot

Applied DNA Sciences: Fiscal Q2 Earnings Snapshot

APDN : 0.1771 (-5.29%)
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results...

APDN : 0.1771 (-5.29%)

Business Summary

Applied DNA Sciences, Inc. provides proprietary DNA-embedded biotechnology security solutions, using non-human DNA, that verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion. They develop, market,...

See More

Key Turning Points

3rd Resistance Point 0.2093
2nd Resistance Point 0.2013
1st Resistance Point 0.1892
Last Price 0.1771
1st Support Level 0.1691
2nd Support Level 0.1611
3rd Support Level 0.1490

See More

52-Week High 14.4000
Fibonacci 61.8% 8.9452
Fibonacci 50% 7.2602
Fibonacci 38.2% 5.5752
Last Price 0.1771
52-Week Low 0.1204

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar